Supreme Court reinstates access to abortion drug mifepristone by mail

The Supreme Court has temporarily allowed health care providers to continue prescribing and mailing abortion medication, mifepristone, until at least May 11. This decision pauses a lower court ruling that had banned such practices. The case stems from a 2025 lawsuit by Louisiana against the FDA over a rule permitting telehealth prescriptions of mifepristone, even in states with abortion bans. An appeals court recently halted these prescriptions during an ongoing FDA review, but the Supreme Court’s stay, following emergency requests from drugmakers, allows telemedicine prescriptions to continue for now. Justice Alito has asked for legal briefs by Thursday, after which the Court will decide on further actions. This issue is crucial as it impacts access to abortion and miscarriage care. Julia Kaye from the ACLU emphasized the importance of resolving this matter to protect reproductive freedom. QUESTION: How might the Supreme Court’s final decision on this case influence access to reproductive health care in the future?